145 related articles for article (PubMed ID: 30324292)
21. The Association of Industry Payments to Physicians with Prescription of Brand-Name Intranasal Corticosteroids.
Morse E; Fujiwara RJT; Mehra S
Otolaryngol Head Neck Surg; 2018 Sep; 159(3):442-448. PubMed ID: 29865931
[TBL] [Abstract][Full Text] [Related]
22. High Costs and Caution Yield Slow Start for New Heart Drugs.
Kuehn BM
Circulation; 2018 Jan; 137(2):197-199. PubMed ID: 29311350
[No Abstract] [Full Text] [Related]
23. Industry Payments to Physicians for Opioid Products, 2013-2015.
Hadland SE; Krieger MS; Marshall BDL
Am J Public Health; 2017 Sep; 107(9):1493-1495. PubMed ID: 28787210
[TBL] [Abstract][Full Text] [Related]
24. County and Physician Variation in Benzodiazepine Prescribing to Medicare Beneficiaries by Primary Care Physicians in the USA.
Maust DT; Lin LA; Blow FC; Marcus SC
J Gen Intern Med; 2018 Dec; 33(12):2180-2188. PubMed ID: 30251216
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Industry Payments to Physicians and Advanced Practice Clinicians.
Zhang AD; Anderson TS
JAMA; 2022 Dec; 328(24):2452-2455. PubMed ID: 36315190
[TBL] [Abstract][Full Text] [Related]
26. Medicare fees and physicians' medicare service volume: beneficiaries treated and services per beneficiary.
Hadley J; Reschovsky JD
Int J Health Care Finance Econ; 2006 Jun; 6(2):131-50. PubMed ID: 16783506
[TBL] [Abstract][Full Text] [Related]
27. Association of Pharmaceutical Industry Marketing of Opioid Products to Physicians With Subsequent Opioid Prescribing.
Hadland SE; Cerdá M; Li Y; Krieger MS; Marshall BDL
JAMA Intern Med; 2018 Jun; 178(6):861-863. PubMed ID: 29799955
[TBL] [Abstract][Full Text] [Related]
28. Trends in Medicare Part D prescription claims for biologic and nonbiologic immunosuppressive medications by dermatologists.
Gronbeck C; Feng PW; Feng H
J Am Acad Dermatol; 2021 Mar; 84(3):848-851. PubMed ID: 33068642
[No Abstract] [Full Text] [Related]
29. The practitioner, the patient, the resident, and the pharmaceutical "gift".
Harlass FE; Uharriet P; Sakakini J
Mil Med; 1995 Sep; 160(9):A10. PubMed ID: 7478023
[No Abstract] [Full Text] [Related]
30. Industry-sponsored meal payments are associated with prescriptions and Medicare expenditures on brand-name colchicine in the United States.
Murayama A
Int J Rheum Dis; 2024 Jan; 27(1):e14962. PubMed ID: 37923570
[TBL] [Abstract][Full Text] [Related]
31. Five-Year Trends in Payments for Neurologist-Prescribed Drugs in Medicare Part D.
de Havenon A; Delic A; Dehoney S; Whetman P; Sheibani N; Callaghan B; Ney J; Esper GJ; Magliocco B; Nair KV
Neurology; 2021 Apr; 96(16):e2132-e2137. PubMed ID: 33692164
[TBL] [Abstract][Full Text] [Related]
32. Association of Pharmaceutical Industry Payments to Physicians With Prescription and Medicare Expenditures for Pimavanserin.
Mehta HB; Moore TJ; Alexander GC
Psychiatr Serv; 2021 Jan; 72(1):77-80. PubMed ID: 32838675
[TBL] [Abstract][Full Text] [Related]
33. Medicare Part D payments for brand and generic drugs prescribed by dermatologists.
Powell HB; Adamson AS
J Am Acad Dermatol; 2018 Sep; 79(3):575-577. PubMed ID: 29477736
[No Abstract] [Full Text] [Related]
34. A few specialty drug prices fall--all generics.
Manag Care; 2008 Dec; 17(12):46. PubMed ID: 19127766
[No Abstract] [Full Text] [Related]
35. Exploring the Industry-Dermatologist Financial Relationship: Insight From the Open Payment Data.
Feng H; Wu P; Leger M
JAMA Dermatol; 2016 Dec; 152(12):1307-1313. PubMed ID: 27706478
[TBL] [Abstract][Full Text] [Related]
36. The role of industry influence in sinus balloon dilation: Trends over time.
Gadkaree SK; Rathi VK; Gottschalk E; Feng AL; Phillips KM; Scangas GA; Metson R
Laryngoscope; 2018 Jul; 128(7):1540-1545. PubMed ID: 29737532
[TBL] [Abstract][Full Text] [Related]
37. Margaret McCartney: Second use patents--why do we have to prescribe branded Lyrica for pain?
McCartney M
BMJ; 2015 May; 350():h2734. PubMed ID: 25995105
[No Abstract] [Full Text] [Related]
38. Association Between Open Payments-Reported Industry Transfers of Value and Prostaglandin Analog Prescribing in the US.
Nguyen AM; Anderson KE; Anderson G; Johnson TV
JAMA Ophthalmol; 2022 Sep; 140(9):855-862. PubMed ID: 35900736
[TBL] [Abstract][Full Text] [Related]
39. Trends in Opioid Prescription in Children and Adolescents in a Commercially Insured Population in the United States, 2004-2017.
Gagne JJ; He M; Bateman BT
JAMA Pediatr; 2019 Jan; 173(1):98-99. PubMed ID: 30419137
[TBL] [Abstract][Full Text] [Related]
40. Bad Medicine: Polypharmacy.
Spence D
Br J Gen Pract; 2017 Dec; 67(665):562. PubMed ID: 29192108
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
